Interferon-β1b increases Th2 response in neuromyelitis optica

Area of Science:

• Neuroimmunology
• Immunotherapy
• T-cell responses

Background:

• Interferon beta-1b (IFN-β1b) is effective for multiple sclerosis (MS) but not neuromyelitis optica (NMO).
• Differential immune responses to IFN-β may explain varying treatment efficacy in MS and NMO.
• Investigating chemokine receptor expression on T-cells can elucidate treatment response differences.

Purpose of the Study:

• To longitudinally assess chemokine receptor expression (CCR5, CXCR3, CCR4) on T-cells in NMO and MS patients undergoing IFN-β1b therapy.
• To correlate changes in T-cell chemokine receptor expression with clinical outcomes (relapse rates).
• To understand the immunological basis for differential responses to IFN-β1b in NMO versus MS.

Main Methods:

• Longitudinal analysis of blood samples from NMO and MS patients over 12 months of IFN-β1b treatment.
• Flow cytometry to quantify CCR5, CXCR3, and CCR4 expression on CD4+ and CD8+ T-cells.
• Comparison of chemokine receptor expression and annualized relapse rates before and after treatment.

Main Results:

• IFN-β1b decreased relapse rates in MS but not in NMO patients.
• No significant baseline differences in chemokine receptor expression between NMO and MS groups.
• IFN-β1b treatment reduced Th1-associated cells (CD4+CCR5+, CD4+CXCR3+) in both NMO and MS.
• IFN-β1b treatment decreased Th2-associated cells (CD4+CCR4+) in MS but significantly increased them in NMO.

Conclusions:

• IFN-β1b therapy induces a Th2-predominant immune response in NMO patients.
• This IFN-β1b-induced Th2 up-modulation in NMO may underlie the lack of therapeutic benefit and potential worsening.
• Th2 pathway involvement is implicated in the pathogenesis of NMO, differentiating it from MS immunopathology.